ProQR Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- ProQR Therapeutics's estimated annual revenue is currently $37.8M per year.
- ProQR Therapeutics's estimated revenue per employee is $230,610
- ProQR Therapeutics's total funding is $358.4M.
Employee Data
- ProQR Therapeutics has 164 Employees.
- ProQR Therapeutics grew their employee count by 7% last year.
ProQR Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | 0% | N/A | N/A |
#3 | $4.2M | 27 | 35% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $1.4M | 9 | 29% | N/A | N/A |
#6 | $235M | 246 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 37 | 76% | N/A | N/A |
#10 | $5.3M | 34 | 0% | N/A | N/A |
What Is ProQR Therapeutics?
Changing lives is what drives us at ProQR Therapeutics. With a highly energetic team of professionals we strive to make a meaningful impact on the lives of patients and the people around them. By combining innovative technologies and entrepreneurism, ProQR is developing products to potentially transform the lives of patients suffering from severe genetic disorders. If you are up to this challenge and like to be part of our team, check out our website for vacancies: www.proqr.com/careers
keywords:N/A
$358.4M
Total Funding
164
Number of Employees
$37.8M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ProQR Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate Director Regulatory Affairs | |
2 | Clinical Data Manager | |
3 | TMF Manager | |
4 | VP Medical Affairs | |
5 | Senior Scientist | |
6 | Chief Financial Officer | |
7 | VP - Global Project Leader & Head Project Management | |
8 | Senior Director, Clinical Research | |
9 | Chief Scientific Officer | |
10 | Researcher |
ProQR Therapeutics News
ProQR Therapeutics (NASDAQ: PRQR) has recently received a number of price target changes and ratings updates: 4/19/2022 ProQR Therapeutics...
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company),...
By Rob Curran. ProQR Therapeutics NV said it would overhaul its drug-development operations, laying off 30% of its employees and a key...
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing platform and strengthens financial position with $50 million i ...
Netherlands-based ProQR is developing its experimental therapy, QR-421a, as a treatment for Usher syndrome. The rare disorder is caused by mutations to genes that provide the instructions for proteins key to hearing, vision, and balance. The disorder is classified under three types, according to ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $48.7M | 164 | -32% | N/A |
#2 | $51.8M | 165 | 35% | $39.8M |
#3 | $25.6M | 165 | 11% | N/A |
#4 | $18.7M | 165 | 32% | N/A |
#5 | $29.2M | 166 | N/A | N/A |